CANTON, Mass., Feb. 15 /PRNewswire-FirstCall/ -- Avitar, Inc., , developer of the world’s first on-site, oral test for drugs-of-abuse, is hosting a construction safety and drug abuse executive roundtable that will feature prominent spokespeople from across the Construction, Risk Management and Insurance industries. The event will take place on February 27, 2006 from 9:30 am to 12:30 pm at the Newton Marriott, Newton, MA. Steve Turko, National Accounts Director for Construction of Avitar will moderate the roundtable.
“The direct correlation between drug abuse and safety at construction sites is well established. While there are many benefits to reducing employee drug use, one of the most important is reducing the number of preventable on- the-job accidents,” Peter P. Phildius, Chairman and CEO, commented. “The profile of the participants and audience of this executive roundtable is a testament to the fact that organizations across the country are realizing the devastating effects of employee drug use and they are serious about implementing innovative programs to address the problem.”
Roundtable participants include: * Perini Corp, Roger Bruce, Corporate Safety Director * Gilbane Building Company, Tony O’Dea, Corporate Safety Manager * Impact, Robert Banks, Director * The Facchina Group of Companies, Joseph J. Poliafico, Director, Risk Management and Human Resources * Aon Risk Services, Glenn Narrow, Senior Risk Control Specialist
Discussions will focus on current and future trends, as well as participants’ experiences with drug-free workplace programs, drug testing and their impacts upon job site safety.
Individuals wishing to attend the event can visit Avitar at http://www.avitarinc.com for registration information.
About Avitar
Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen(R), the world’s first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB(R), an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar’s website at http://www.avitarinc.com.
Company Contact: PR Contact: Peter Cholakis Maura Landry Avitar Inc. SHIFT Communications 781-821-2440 x117 617-681-1229 pcholakis@avitarinc.commlandry@shiftcomm.com
Avitar, Inc.
CONTACT: Peter Cholakis of Avitar Inc., +1-781-821-2440, ext. 117,pcholakis@avitarinc.com; or Maura Landry of SHIFT Communications for AvitarInc., +1-617-681-1229, mlandry@shiftcomm.com
Web site: http://www.avitarinc.com//
